Clinical application of VerifyNow-P2Y12 assay in evaluation of platelet inhibition efficacy of clopidogrel

• Published in: Zhōnghuá xīnxuèguănbìng zázhì Vol. 40; no. 8; p. 662
• Main Authors: Lin, Shao-yi, Cui, Han-bin, Chen, Xiao-min, Wang, Sheng-huang, Zhou, Hong-lin, DU, Wei-ping, Ye, Hong-hua, Pan, Wei-min, Yang, Rui, Feng, Ming-jun, Hu, Ye-wen, Wang, Yong, Wang, Shi-qi
• Format: Journal Article
• Language: Chinese
• Published: China 01.08.2012
• Subjects: Aged; Angioplasty, Balloon, Coronary; Female; Humans; Male; Middle Aged; Platelet Aggregation - drug effects; Platelet Aggregation Inhibitors - pharmacology; Platelet Function Tests; Receptors, Purinergic P2Y12; Ticlopidine - analogs & derivatives; Ticlopidine - pharmacology
• ISSN: 0253-3758
• DOI: 10.3760/cma.j.issn.0253-3758.2012.08.008

To evaluate the platelet inhibition efficacy in patients under regular maintenance dose of clopidogrel by VerifyNow-P2Y12 assay and explore the clinical characteristics of clopidogrel non-responders and related predicting factors. A total of 99 patients underwent percutaneous coronary intervention procedure and receiving clopidogrel in regular maintenance dose for at least 1 week were enrolled. Platelet reactivity, including baseline, P2Y12 reaction unit (PRU), and platelet inhibition rate were measured with VeifyNow-P2Y12 assay. The dosage of anti-platelet drugs, combination with any other drugs, clinical characters in baseline of all enrolled patients were analyzed. PRU ≤ 240 was used as cut-off to identify clopidogrel responder and clopidogrel non-responder. In the non-responder group, patients were further separated into 3 sub-groups (types) according to the baseline and platelet inhibition rate: type I with high baseline, high inhibition rate, representing false non-responder; type II with low inhibition